Novartis Announces Leadership Restructuring for Innovative Medicines China

Recently, Novartis China has also begun a new structural adjustment. The personnel structure of Novartis' innovative drug China management team has been announced and will be officially implemented on June 1st, next month.

The specific appointments are as follows:

Zhang Ying, President and Managing Director of Innovative Drugs China, will serve as the interim head of the cardiovascular therapeutic area for Innovative Drugs China. Johan Kahistroem, the current head of the Cardiovascular, Renal, and Metabolic Diseases Business Unit, will transition to another role within the company.

Yan Qiong Appointed as Head of Innovative Drugs China Immunotherapy Field. County Teams to Continue Reporting to Yan Qiong.

Dario Drago Will Serve as the Interim Head of Innovative Medicines China Oncology. The Announcement States That the Selection Process for the Head of the Oncology Field Is Underway.

Jack Wang Jia to Serve as Head of Innovative Drugs for Ophthalmology, Transplantation, and Central Nervous System (OTN) in China

Chen Hui Appointed as Head of Innovative Drugs China Retail, Emerging Markets and Commercial Department

Yifan Zhang Appointed as Head of Business Excellence and Operations (BEE) for Innovative Medicines China

Wu Ling Appointed as Head of Innovative Drug China Medical Affairs and Chief Medical Officer

Luo Ya Appointed as Head of Innovative Drug China Value Access Department

Seymour Gail Appointed as Head of Innovative Medicines China Strategy and New Product Planning Department

Chang Xuelun Helen Appointed as Head of Strategic Growth Initiatives for Innovative Medicines in China